Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of Kosan's product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; Kosan's reliance on Pfizer for the potential manufacture, development and commercialization of any compounds from Kosan's motilin agonist program, including PF-04548043; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... SAN DIEGO, May 26, 2011 Volcano Corporation ... following statement: Earlier this year, the ... a wholly-owned subsidiary of St. Jude Medical, that ... misappropriated LightLab,s confidential information in connection for use ...
... YORK, May 26, 2011 A new prostate cancer ... Medicine comparing surgical treatment to "watchful waiting" ... cancer and currently debating their treatment options. ... the most commonly offered clinical options for early prostate ...
Cached Medicine Technology:Statement From Volcano Corporation on Latest St. Jude Lawsuit 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... by People Magazine in the article Mike 'The Situation' ... (7/15), one of the most popular cast stars from MTV's ... about his personal transformation. Now, two years later since the ... with his life was a challenge. He was previously addicted ... even spent some time in rehab. He took the opportunity ...
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
(Date:7/25/2014)... 2014 Ticket Down is a ... tickets in Berkeley at California Memorial Stadium. With the ... of football, the organizers of the 2014 Guinness International Champions ... to North America. With teams representing La Liga, English Premier ... some of the best football players from around the world ...
(Date:7/25/2014)... July 25, 2014(BRONX, NY)A study involving nearly 27,000 older ... 10 met criteria for pre-dementia based on a simple ... they have cognitive complaints. People who tested positive for ... dementia within 12 years. The study, led by scientists ... Yeshiva University and Montefiore Medical Center , was ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4
... us are counting,down the days leading up to the ... Council of America reminds you that time is running ... your flexible spending,account., Made available through employers, flexible ... pay for out-of-pocket health expenses,such as an eye exam ...
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... A study led by Massachusetts General Hospital (MGH) researchers ... fibrosis (IPF), a usually fatal lung disease for which ... that a specific molecular pathway appears responsible for key ... IPF, the cause of which is currently unknown. ...
... has been shown to improve the sleep quality and ... most commonly-used medication, according to research published today in ... the effects of the new drug dexmedetomidine with the ... pain and anxiety experienced by mechanically ventilated ICU patients ...
... Philadelphia, PA, December 12, 2007 Major depressive disorder ... almost one in five individuals. More than 75% of ... have at least one recurrence, with the majority having ... disability of all medical illnesses, with substantial functional impairment, ...
... the fight against cancer: Recent research at the University ... Ganoderma lucidum aid in suppressing some of the mechanisms ... action of the fungus: disrupting androgen receptor activity and ... the past 3-4 decades much scientific research has dealt ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Molecular pathway appears crucial in development of pulmonary fibrosis 2Health News:Intensive care quality of sleep improved by new drug, reports study 2Health News:Venlafaxine extended-release effective for patients with major depression 2Health News:Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: